Clinical significance of SIRT3 and inflammatory factors in multiple myeloma patients with bortezomib-induced peripheral neuropathy: a cohort study

References

• Wang S, Xu L, Feng J, et al. Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis. Front Oncol. 2020;9:1513.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Egashira N. Pathological mechanisms of bortezomib-induced peripheral neuropathy. Int J Mol Sci. 2021;22(2):888.
   PubMed Web of Science ®Google Scholar
• Robak P, Drozdz I, Szemraj J, et al. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199–208.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609–2617.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745–4753.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679–686.
   PubMed Web of Science ®Google Scholar
• Kharel P, Uprety D, Chandra AB, et al. Bortezomib-induced pulmonary toxicity: a case report and review of literature. Case Rep Med. 2018;2018:2913124.
   PubMed Web of Science ®Google Scholar
• Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016;32(1):95–103.
   PubMed Web of Science ®Google Scholar
• Li J, Chen S, Hu Y, et al. Bortezomib-induced severe pulmonary complications in multiple myeloma: a case report and literature review. Oncol Lett. 2016;11(3):2255–2260.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113–3120.
   PubMed Web of Science ®Google Scholar
• Hu B, Zhou Q, Wu T, et al. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis. Int J Clin Pharmacol Ther. 2017;55(4):329–338.
   PubMed Web of Science ®Google Scholar
• Colson K, Doss DS, Swift R, et al. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs. 2004;8(5):473–480.
   PubMedGoogle Scholar
• Colson K, Doss DS, Swift R, et al. Expanding role of bortezomib in multiple myeloma: nursing implications. Cancer Nurs. 2008;31(3):239–249.
   PubMed Web of Science ®Google Scholar
• Chung T, Prasad K, Lloyd TE. Peripheral neuropathy: clinical and electrophysiological considerations. Neuroimaging Clin N Am. 2014;24(1):49–65.
   PubMed Web of Science ®Google Scholar
• Jin HY, Park TS. Role of inflammatory biomarkers in diabetic peripheral neuropathy. J Diabetes Investig. 2018;9(5):1016–1018.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Laubach JP, Giove TJ, et al. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. Br J Haematol. 2017;178(5):756–763.
   PubMed Web of Science ®Google Scholar
• Anderson KC, Alsina M, Atanackovic D, et al. Multiple myeloma, version 2.2016: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2015;13(11):1398–1435.
   PubMedGoogle Scholar
• Tong Y, Guo H, Han B. Fifteen-day acupuncture treatment relieves diabetic peripheral neuropathy. J Acupunct Meridian Stud. 2010;3(2):95–103.
   PubMedGoogle Scholar
• Leal AD, Qin R, Atherton PJ, et al. North Central cancer treatment group/alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014;120(12):1890–1897.
   PubMed Web of Science ®Google Scholar
• Blimark C, Holmberg E, Mellqvist U-H, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–113.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management . Am J Hematol. 2020;95(5):548–567.
   PubMed Web of Science ®Google Scholar
• Li T, Timmins HC, King T, et al. Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase III trials. Hematol Oncol. 2020;38(3):229–243.
   PubMed Web of Science ®Google Scholar
• Zhi WI, Ingram E, Li SQ, et al. Acupuncture for bortezomib-induced peripheral neuropathy: not just for pain. Integr Cancer Ther. 2018;17(4):1079–1086.
   PubMed Web of Science ®Google Scholar
• Maschio M, Zarabla A, Maialetti A, et al. Prevention of bortezomib-related peripheral neuropathy with docosahexaenoic acid and α-lipoic acid in patients with multiple myeloma: preliminary data. Integr Cancer Ther. 2018;17(4):1115–1124.
   PubMed Web of Science ®Google Scholar
• Berkowitz A, Walker S. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Clin J Oncol Nurs. 2012;16(1):86–89.
   PubMed Web of Science ®Google Scholar
• Zhao W, Wang W, Li X, et al. Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-α. Ann Hematol. 2019;98(12):2793–2803.
   PubMed Web of Science ®Google Scholar
• Moschetti G, Amodeo G, Maftei D, et al. Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy. J Neuroinflammation. 2019;16(1):1–16.
   PubMedGoogle Scholar
• Min CK, Lee S, Kim YJ, et al. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Eur J Haematol. 2006;76(3):265–268.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Gercheva L, Williams C, et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol. 2015;90(1):42–49.
   PubMed Web of Science ®Google Scholar
• Dikalova AE, Pandey A, Xiao L, et al. Mitochondrial deacetylase Sirt3 reduces vascular dysfunction and hypertension while Sirt3 depletion in essential hypertension is linked to vascular inflammation and oxidative stress. Circ Res. 2020;126(4):439–452.
   PubMed Web of Science ®Google Scholar
• Kurundkar D, Kurundkar AR, Bone NB, et al. SIRT3 diminishes inflammation and mitigates endotoxin-induced acute lung injury. JCI Insight. 2019;4(1), e120722. doi: https://doi.org/10.1172/jci.insight.120722
   PubMed Web of Science ®Google Scholar
• Qiao Y, Xu L, Tao X, et al. Protective effects of dioscin against fructose-induced renal damage via adjusting Sirt3-mediated oxidative stress, fibrosis, lipid metabolism and inflammation. Toxicol Lett. 2018;284:37–45.
   PubMed Web of Science ®Google Scholar